H.C. Wainwright raised the firm’s price target on AngioDynamics (ANGO) to $16 from $15 and keeps a Buy rating on the shares. The company reported a beat in fiscal Q3 and raised its fiscal 2025 guidance, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics’ Strong Performance and Growth Potential Justifies Buy Rating
- AngioDynamics Reports Strong Growth in Med Tech Segment
- AngioDynamics’ Earnings Call Highlights Growth and Optimism
- Tesla reports deliveries miss, Nintendo says Switch 2 out in June: Morning Buzz
- AngioDynamics to Host Virtual Cardiovascular Investor Event